Navigation Links
Resverlogix Notice of Conference Call & Webcast

TSX Exchange Symbol: RVX

CALGARY, Aug. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on August 25, 2008 at 11:00 am MDT to provide a corporate update of the Company. Following the presentation there will be a live question and answer session.

The webcast can be accessed at the following link:

Participants can also dial in for the conference call:

Dial information is as follows:

North American Toll Free Dial In: 1-800-319-4610

International Dial In: +1-604-638-5340

The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Jan Gray Joins Resverlogix Board of Directors
2. Resverlogixs Lead Drug Featured in Key Scientific Publication
3. Industry Leaders Select Resverlogixs RVX-208
4. /C O R R E C T I O N from Source -- Resverlogix Corp./
5. Resverlogix Notice of Conference Call & Webcast
6. Resverlogix Share Option Extension
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
9. Resverlogix is Presenting at IAS HDL Workshop
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... SPIE Photonics Europe 2016, the premier research conference in Europe on photonics, ... run 4-7 April 2016 in the Square Brussels Meeting Centre. Complete information ...
(Date:12/1/2015)... , Dec. 1, 2015  Twist Bioscience, a company focused ... Leproust , Ph.D., has been selected as one of ... fast-tracking the building blocks of life . Each year, ... whose contributions and work have changed lives and are ... "It is an honor to be recognized among these ...
(Date:12/1/2015)... 2015 ... "2016 Europe Cell Surface Markers: Country ... Strategies, Opportunities for Suppliers--France, Germany, Italy, Spain, ... --> ) has announced the ... Surface Markers: Country Volume and Sales Forecasts, ...
(Date:12/1/2015)... Texas (PRWEB) , ... December ... ... , a leading relationship marketing company specializing in scientifically backed, age-defying products, ... January 2016 issue, which highlights the exponential success and unrivaled opportunities that ...
Breaking Biology Technology:
(Date:11/30/2015)... DEERFIELD BEACH, Fla. , Nov. 30, 2015 ... selected as a finalist in this year,s Fierce Innovation ... publisher of FierceHealthIT , ... BIOCLAIM was recognized as a finalist in the ... --> ...
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
Breaking Biology News(10 mins):